Chinese Heavyweight Anti-Cancer Drugs "Group Up" for Global Export: PLD, Bortezomib, Erlotinib, and PEG-GCSF Revolutionizing the Worldwide P

At DengYueMed, we are witnessing and actively driving a profound transformation in the global oncology treatment landscape—from drug shortages and originator monopolies to a more diversified supply chain and multi-market collaboration. Our latest cross-border partnerships incorporate key clinical products such as albumin-bound paclitaxel, liposomal doxorubicin, liposomal irinotecan, sorafenib, imatinib, and bleomycin into international supply systems. These collaborations span formulation development, CTD/DMF registration support, clinical trial drug supply, and multi-regional commercialization and distribution.

This systemic approach signals a shift in global oncology drug supply from single-source dependency to a multi-center, standardized, and sustainable model. It also underscores DengYueMed's evolving role in the global supply ecosystem, transitioning from a manufacturing participant to a strategic collaborator.

Global Cancer Burden Continues to Rise, Widening Treatment Gaps

According to GLOBOCAN 2024 data, new cancer cases worldwide have exceeded 20 million, with projections reaching over 24 million by 2035. High-incidence cancers like breast, lung, liver, prostate, and leukemia persist, with treatment disparities most pronounced in low- and middle-income countries.

In this context, traditional chemotherapies and classic targeted therapies remain foundational. For instance:

• Paclitaxel for Injection (Albumin-Bound): A cornerstone for first-line breast cancer chemotherapy.
• Doxorubicin HCl Liposome Injection, Mitoxantrone HCl Liposome Injection, Irinotecan Liposome Injection: Enhancing efficacy while reducing cardiotoxicity and adverse reactions.
• Sorafenib Tosylate Tablets, Sunitinib Malate Capsules, Imatinib Mesylate Tablets, Erlotinib Hydrochloride Tablets: Covering targeted pathways for liver cancer, renal cell carcinoma, gastrointestinal tumors, leukemia, and lung cancer.
• Bortezomib for Injection: A core component in multiple myeloma regimens.

Global demand for these drugs is growing, yet challenges in pricing, accessibility, and supply continuity persist in many regions, making stable, compliant cross-border supply a strategic imperative.

Target Mechanisms and Product Value: Building a Multi-Layered Anti-Tumor Ecosystem from Traditional Chemotherapy to Precision Targeting

From DengYueMed's perspective, the current anti-tumor treatment system is forming a comprehensive ecosystem comprising cytotoxic chemotherapy, advanced formulations, and precision-targeted drugs, each playing an irreplaceable role in clinical practice.

1. Traditional Cytotoxic Chemotherapy: Still the Foundational Framework in Global Guidelines

Drugs like paclitaxel, irinotecan, and mitoxantrone interfere with cell cycles and DNA replication, remaining core to first-line solid tumor treatments. Global guidelines (NCCN, ESMO) continue to endorse them as preferred options, indicating chemotherapy's enduring relevance.

2. Liposomal Formulations: A Key Path to Modernizing Chemotherapy

Liposomal doxorubicin and mitoxantrone optimize drug distribution to:

• Reduce cardiotoxicity
• Extend plasma half-life
• Increase tumor tissue exposure

Liposomal technology represents a "second life cycle" for chemotherapeutics, emerging as one of the fastest-growing oncology sub-segments globally.

3. Small-Molecule Targeted Therapies: Shifting Cancer from Fatal Disease to Chronic Management

• Sorafenib: The first targeted therapy to improve liver cancer survival.
• Sunitinib: Multi-target coverage for renal cancer and GIST.
• Imatinib: A milestone in transforming CML from high-mortality to high-survival.
• Erlotinib: Standard first-line for EGFR-mutated lung cancer.

These agents feature long treatment durations, high repurchase rates, and stringent supply stability requirements, making them focal points for multinational collaborations and global distribution.

4. PEG-G-CSF: A Strong Addition to the Anti-Tumor Supply Chain

Beyond core chemotherapies and targeted drugs, supportive care medications are vital for treatment stability. At DengYueMed, we recognize the surging demand for PEG-G-CSF (long-acting pegylated granulocyte colony-stimulating factor) amid rising global chemotherapy patient volumes.

PEG-G-CSF extends G-CSF's half-life, significantly reducing chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) risks, lowering hospitalization rates, and improving patients' ability to complete chemotherapy cycles.

In international guidelines (NCCN/ESMO), PEG-G-CSF is standard prophylaxis for high-risk regimens, with rapid growth in:

• High-intensity schemes for breast, lung, and gastrointestinal cancers
• Patients on taxane/anthracycline-based therapies
• Immune support for multiple myeloma and lymphoma
• Emerging markets' demand for long-acting alternatives

High costs and single-source structures for originator products create accessibility gaps worldwide, positioning PEG-G-CSF as a key addition in cross-border partnerships. By integrating it into our supply systems, DengYueMed enriches oncology portfolios and completes the "core therapeutics + supportive care" ecosystem, offering global clinicians more robust, stable solutions.

When More Drugs Become Visible, Affordable, and Accessible, Cancer Treatment Takes on New Meaning

In hospitals and oncology clinics worldwide, these supply chain upgrades have tangible impacts far beyond industry metrics. Patients are experiencing real changes: treatments no longer interrupted by shortages or deterred by high originator prices.

In a Latin American regional medical center, breast cancer patient Maria once resorted to higher-side-effect alternatives due to unaffordable PLD; now, with our cross-border systems, she accesses safer, more tolerable liposomal doxorubicin. In South Asia, CML patient Rahim struggled with imatinib's costs for consistent dosing—multi-sourcing now enables standard adherence, facilitating chronic management. In Eastern European oncology wards, improved bortezomib and erlotinib stability allows physicians to follow guidelines without inventory-based adjustments.

For chemotherapy patients, PEG-G-CSF's inclusion transforms outcomes. Previously, severe neutropenia meant recurrent hospitalizations, infections, and delays; enhanced long-acting accessibility now supports smoother cycles, fewer complications, preserved energy, and better quality of life.

For millions of global cancer patients, "supply chain upgrades" translate to fewer side effects, higher survival rates, stable treatment paths, and genuine hope.

Market Analysis and Commercialization Potential: Global Anti-Tumor Drug Market in Steady Expansion

Reports from Market Research Future, Evaluate Pharma, and Fortune BI indicate the global oncology market surpassing $200 billion, with 10–12% CAGR projected. Targeted therapies, liposomal chemotherapeutics, and injectables are among the fastest-growing, most competitive segments.

Key trends include:

• Sorafenib and sunitinib maintaining strong demand in emerging markets like Southeast Asia, Middle East, and Latin America, with rising penetration.
• Liposomal doxorubicin (PLD) growing at nearly 14% annually, driven by superior safety and administration.
• Erlotinib and imatinib holding top sales due to stable patient bases and long-term dosing.
• Bortezomib accelerating with multiple myeloma diagnostics expansion, boosting supply needs.

DengYueMed leverages our "stable quality + comprehensive registration data + agile supply chain" strengths to claim a growing share in global markets, serving as essential supplements and partners in international oncology frameworks.

Industry and Policy Context: Maturing Innovative Drug Ecosystems and Export Regulations

As domestic policies align with international standards, DengYueMed benefits from an optimizing environment for Chinese export pharma.

Key drivers include:

• Priority reviews and breakthrough pathways accelerating innovative drug launches.
• ICH membership ensuring systemic consistency in quality and registration.
• Multi-regional clinical trials (MRCT) enabling global synchronous development.
• Consistency evaluations elevating oral solid dosage quality for overseas competitiveness.
• Internationalized GMP and quality systems gaining multinational recognition.
• Streamlined export regulations clarifying global market pathways.

This collaboration is more than commercial—it's a signal of Chinese generics' comprehensive capabilities in R&D, production, global registration, and supply management entering a new upgrade phase.

Conclusion

From global demand, policy landscapes, to enterprise capabilities, a clear trend emerges: Synergistic chemotherapy and targeted drug portfolios, maturing liposomal technologies, and advancing exports/registrations position DengYueMed as a pivotal player in the global anti-tumor drug system. This partnership reflects the rational, steady, and mature internationalization of China's pharmaceutical industry.

Guided by commitments to excellence, innovation, sustainability, and social responsibility, DengYueMed—with quality, compliance, and integrity as our foundation—is poised to lead Chinese pharma exports to new heights, contributing to global health and well-being.